Dataset opportunity
Bellaseno — 医疗影像数据集机会
Bellaseno 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
73
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球诊断人工智能市场在 2025 年的估值为 20 亿美元，预计复合年增长率为 21.7%（2026-2033 年）。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-10
Breast augmentation procedure uses 3D-printed scaffolds
labonline.com.au ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Bellaseno 持有重要的医疗影像数据集，模态为图像，并附带相关的医疗记录和工业数据。这个丰富、多方面的数据集特别适合开发和训练高精度的诊断人工智能算法，尤其是在重建医学领域，这是 Bellaseno 的核心业务领域。
该数据的商业价值体现在全球诊断人工智能市场上，该市场在 2025 年的估值为 20 亿美元，预计将以 21.7% 的复合年增长率增长。[1] 尽管存在已知的访问复杂性，例如严格的 GDPR 合规性、与 Mentor (Johnson & Johnson) 就乳房应用达成的限制性许可协议，以及数据分布在德国和澳大利亚子公司，但该数据集的稀有性和特异性使其成为针对这个高增长市场的 AI 开发者的宝贵资产。⚠ 尽职调查（有价值的数据，可协商访问）：临床数据受严格的 GDPR 和医疗隐私法规约束；与 Mentor (Johnson & Johnson) 的独家全球许可协议可能会限制乳房应用的数据权；数据部分分布在德国和澳大利亚子公司。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据表明 Bellaseno 持有一个稀有的纵向医疗影像数据集，具有长达6 年的随访数据，直接将MRI和CT 扫描与患者结果和支架制造参数联系起来。这个专有集合对于寻求训练和验证预测术后组织再生和植入物性能的算法的诊断人工智能公司来说是关键资产。在诊断人工智能市场预计每年增长超过 21% 的情况下，该数据集通过支持下一代个性化医疗预测模型的开发，提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity100
主导的“医疗记录”，医疗保健行业，4 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity94
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value94
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
买家需求异常高，这得益于**诊断人工智能市场**快速的**21.7% 复合年增长率**，这造成了对专业、高质量训练数据的迫切需求，以构建有竞争力的解决方案。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 种证据类型，4 个命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据胃口信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 超出已货币化部分的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — BellaSeno 是一个理想的目标，因为它是一家临床阶段的医疗技术中小型企业，其核心业务是开发专有的可吸收医疗支架，并产生有价值的临床试验和医疗影像数据作为副产品，而这些数据目前并未出售。问题：该公司最近与 Mentor Worldwide LLC（一家 Johnson & Johnson 公司）签署了一项独家全球许可协议，这可能会影响未来的数据权。
- Deep Qualification90
⚠ 需要审查 — Bellaseno 是一家开发可吸收支架的医疗技术公司，其产生的临床试验数据是副产品。虽然这些数据非常有价值且与人工智能机会一致，但与 Mentor (Johnson & Johnson) 就其主要应用（乳房）达成的独家全球许可协议严重限制了数据访问和货币化。[许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该数据集包括来自 45 名以上患者的纵向临床记录，随访时间长达 6 年，为训练预测模型提供了关于患者报告结果和组织保留的关键真实数据。
Image collection
该系列包含多年的术后 MRI 扫描，直观地记录了软组织保留和血管化情况，为用于分析和预测愈合轨迹的人工智能模型提供了宝贵数据。
Industrial data
该数据集丰富了关于可吸收支架制造参数和生物力学特性的专有时间序列数据，使人工智能能够将植入物设计与体内性能相关联。
Geospatial data
该系列包括从CT 扫描的数字分割中提取的表格数据，用于患者特定支架的 3D 重建，这对于开发自动化3D 建模人工智能至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Bellaseno Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global Artificial Intelligence in Diagnostics market was valued at USD 2.0 billion in 2025, with a projected CAGR of 21.7% (2026-2033) (source: Grand View Research). [1]. Investment score 73.0/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Solexperts — 工业传感器数据集机会
View opportunity →工业Abrams — 检验报告数据集机会
View opportunity →工业Tarus — 维护日志数据集机会
View opportunity →